Dermatology
Pyoderma Gangrenosum
17
Pipeline Programs↗
4
Active Trials↗
10
Companies Involved↗
Pyoderma Gangrenosum is an emerging landscape with 17 programs across 10 companies. The most active players are Johnson & Johnson, Eli Lilly, Novartis. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 212
Phase 35
Approved
No programs
Analysis
Modality Breakdown
16programs
Small molecule850%
Monoclonal antibody850%
Modality classified for 95% of 19 pipeline programs.
Analysis
Trial Status
23
clinical trials
Terminated8 · 35%
Completed8 · 35%
Withdrawn3 · 13%
Recruiting2 · 9%
Not yet recruiting2 · 9%
Clinical Trials
Trial Activity
23 trials
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)